STERIS (STE) Q2 2027 Earnings Call Transcript

STERIS reported fiscal Q2 2027 revenue of $1.6 billion, up 9% year over year, and adjusted EPS of $2.94, up 19% (13% excluding tariff refunds). It raised full-year adjusted EPS guidance to $11.35–$11.55 from $11.10–$11.30, while lowering AST organic growth guidance to 6%–7% and lifting Life Sciences guidance to 9%–10%. Results and outlook included a $20 million quarterly tariff refund; management also agreed to acquire Xodus Medical and initiated a restructuring plan with $45 million of anticipated charges and about $9 million in annualized savings.

Analysis

The headline earnings strength is less durable than the guide increase suggests: tariff refunds contributed 130bp to margin expansion and are not expected to recur materially, while underlying margins were slightly lower. That leaves execution—not the reported margin step-up—as the key test of the higher EPS range. The inventory build creates near-term cash-conversion risk, but would be a positive operating signal if it converts into second-half shipments without a subsequent inventory correction.

Across the next 1–3 months, watch AST shipments and customer ordering rather than the easier comparison alone: destocking may have ended, but the reduced growth outlook and lower North American procedural growth point to only a measured recovery. Higher utilization could create meaningful incremental margin leverage at established AST facilities; ramping sites and inflation temper that upside. Life Sciences is a structural beneficiary of localization, but one unusually large capital order and catch-up demand make quarterly growth a poor run-rate proxy. In 6–18 months, Xodus could add recurring OR consumables and a useful clinical sales channel; validate realized cross-selling and deal economics after close, especially given debt funding.

The contrarian read is that the quality of growth matters more than the EPS beat: the market may over-credit temporary tariff relief and episodic Life Sciences equipment, while underweighting the option value of AST utilization and recurring consumables. Restructuring savings are modest relative to the business and should not anchor a margin thesis. Without valuation and post-call price data, there is not enough basis for a fresh outright position.

Key Decisions for Investors

• No immediate directional trade from the transcript alone. Reassess STE after the price reaction against valuation and the durability of earnings excluding tariff refunds.
• Set a 1–3 month alert for AST order/shipment trends and Healthcare inventory conversion. A miss versus the 6%–7% AST growth outlook, or evidence of renewed customer destocking, would weaken the recovery thesis; sustained growth with improving facility leverage would strengthen it.
• Track free-cash-flow conversion and inventory through the second half. If inventory remains elevated without corresponding shipments, treat the cash-flow decline as a demand or execution warning rather than a timing item.
• After Xodus closes, verify purchase economics, incremental interest expense, and evidence of cross-selling into STERIS’s OR customer base before underwriting acquisition accretion.